drugset / Trial / NCT01019928

Esophageal Hypersensitivity Study in Patients With Gastroesophageal Reflux Disease (GERD)

NCT01019928 ↗

Phase 2 Completed 14 enrolled AstraZeneca
RandomizedCrossoverTriple-blindTreatment

Summary

The purpose of the study is to compare sensitivity of visceral pain in the esophagus using different pain stimuli.

Timeline

Start
2009-11
Primary completion
2011-01
Completion
2011-01

Outcome

Missed primary endpoint

paper CONCLUSIONS: AZD1386 had no analgesic effect on experimental esophageal pain in patients with NERD and a partial PPI response PMID 23320520 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1386 Small molecule 95 mg Oral

Indications